Phase 1 Burkitt Lymphoma Clinical Trials
14 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaLymphoma+1 more
National Cancer Institute (NCI)155 enrolled1 locationNCT03223610
Recruiting
Phase 1Phase 2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Diffuse Large B Cell LymphomaEwing SarcomaNeuroblastoma+2 more
Merck Sharp & Dohme LLC90 enrolled70 locationsNCT06395103
Recruiting
Phase 1
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Non-Hodgkin LymphomaPlasmablastic LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI)25 enrolled1 locationNCT05389423
Recruiting
Phase 1Phase 2
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Burkitt LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsDouble-Expressor Lymphoma
National Cancer Institute (NCI)50 enrolled4 locationsNCT07069699
Recruiting
Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaLymphoma+1 more
National Cancer Institute (NCI)55 enrolled1 locationNCT04739813
Recruiting
Phase 1Phase 2
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 1
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaMantle Cell Lymphoma+3 more
Medical College of Wisconsin12 enrolled1 locationNCT05990465
Recruiting
Phase 1
Study of SGR-1505 in Mature B-Cell Neoplasms
High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 1
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaMantle Cell Lymphoma+7 more
C. Babis Andreadis36 enrolled1 locationNCT04545762
Recruiting
Phase 1Phase 2
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Recurrent Burkitt LymphomaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+6 more
M.D. Anderson Cancer Center276 enrolled1 locationNCT01371630
Recruiting
Phase 1
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
High-grade B-cell LymphomaNon-Hodgkin LymphomaFollicular Lymphoma+5 more
Acepodia Biotech, Inc.42 enrolled13 locationsNCT05653271
Recruiting
Phase 1
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Mantle Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Stanford University148 enrolled1 locationNCT06340737
Recruiting
Phase 1
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
Acute Lymphoblastic Leukemia, AdultBurkitt LymphomaLymphoblastic Lymphoma, Adult
Fifth Affiliated Hospital, Sun Yat-Sen University28 enrolled1 locationNCT06060782